Bengaluru, Karnataka, India, November 29, 2016
Biocon, Asia’s premier biopharmaceuticals enterprise and the largest Indian insulins Company, has been engaging with diverse stakeholders to educate them on effective Diabetes Management for Healthy Living, in addition to providing high-quality biopharmaceuticals.
As a part of its social responsibility, Biocon had introduced ABIDE, a unique diabetes education initiative for medical practitioners in year 2012. This initiative has been making a significant impact across the country and has now been conferred with the ‘Award of Recognition’ for it’s benefits, coverage and impeccable quality of delivery by the prestigious Research Society for the Study of Diabetes in India (RSSDI).
The award was received by Dr. Major Guruprasad Thimmaiah, Senior Director & Head – Medical Affairs and ABIDE, Biocon, at the 44th Annual Conference of RSSDI held in Hyderabad recently. This recognition from RSSDI, the largest organization for diabetes researchers and healthcare professionals in Asia, is a validation of the positive impact being made by Biocon’s learning initiative aimed at enhancing the understanding of the disease, diagnosis and treatment, in order to enrich the healthcare ecosystem of India.
ABIDE is a ‘paradigm-shifting’ initiative designed to empower primary care physicians who treat diabetes on a regular basis. The courses, are delivered in a non-commercial setting and offer learning opportunities through ‘experience sharing’ during the intensive deliberations in small group engagements. The pragmatic and application-based approach of ABIDE has helped physicians improve their practice with enriched patient connect and enhanced clinical outcomes. Biocon plans to expand the ambit of the ABIDE program for the benefit of a wider group of healthcare providers.”
Partha Roy Chowdhury, General Manager & Head – Metabolics Division, Branded Formulations, Biocon said, “It is truly an honor and proud moment for team ABIDE to be recognized by the prestigious RSSDI Award. As a compassionate, caring and responsible company, our efforts are aimed at raising awareness on diabetes and empowering the ecosystem to efficiently address patient needs. We aim to intensify our efforts in enabling the physician and paramedics through this school of learning. Since its inception in 2012, ABIDE has completed 75 Courses empowering nearly 3000 physicians spread across 300 towns/cities across India.
The program is powered by a National Panel of passionate, committed and vastly experienced doctors and a Core Committee of the best Endocrinologists in the country.
Research Society for the Study of Diabetes in India founded by Prof. M.M.S. Ahuja in 1972. RSSDI is the largest organization of diabetes health care professionals and researchers in Asia. Currently, life members are represented from 29 Indian States and Union Territories. RSSDI is actively involved in updating the knowledge and skills of physicians. RSSDI TEXT BOOK OF DIABETES MELLITUS is one such endeavour of bringing the latest knowledge on various aspects of diabetes, especially Indian context, to the physicians and primary care practitioners. RSSDI organizes a national conference which not only provides a platform for its members to listen to the leaders in the field of diabetes from within the country as well as from abroad but also to interact among themselves, exchange knowledge and ideas. Annual conferences of RSSDI have been regular feature for last 40 years and are very well attended.
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India’s largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 100 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from ‘Lab to Market’. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™ (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody. It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral insulin analog. For more information, Visit: www.biocon.com